Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7101866 | GLAXO GRP LTD | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
US7361787 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(1 year, 28 days ago) | |
USRE44874 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(1 year, 28 days ago) | |
US7439393 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(1 year, 1 month from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5873360 | GLAXO GRP LTD | Inhalation device |
Feb, 2016
(8 years ago) | |
US6759398 | GLAXO GRP LTD | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
US7629335 | GLAXO GRP LTD | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
US6878698 | GLAXO GRP LTD | Anti-inflammatory androstane derivatives |
Aug, 2021
(2 years ago) | |
US6537983 | GLAXO GRP LTD | Anti-inflammatory androstane derivatives |
Aug, 2021
(2 years ago) | |
US7776895 | GLAXO GRP LTD | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(1 year, 7 months ago) | |
US7439393 (Pediatric) | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
Nov, 2025
(1 year, 7 months from now) | |
US8511304 | GLAXO GRP LTD | Medicament dispenser |
Jun, 2027
(3 years from now) | |
US9333310 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2027
(3 years from now) | |
US8113199 | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
US8511304 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Dec, 2027
(3 years from now) | |
US8161968 | GLAXO GRP LTD | Medicament dispenser |
Feb, 2028
(3 years from now) | |
US9333310 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Apr, 2028
(3 years from now) | |
US8113199 (Pediatric) | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Apr, 2028
(4 years from now) | |
US8161968 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Aug, 2028
(4 years from now) | |
US11116721 | GLAXO GRP LTD | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Feb, 2029
(4 years from now) | |
US11116721 (Pediatric) | GLAXO GRP LTD | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Aug, 2029
(5 years from now) | |
US8534281 | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
US8534281 (Pediatric) | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
US8746242 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2030
(6 years from now) | |
US8746242 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Apr, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | May 13, 2026 |
New Strength(NS) | May 13, 2026 |
Pediatric Exclusivity(PED) | Nov 13, 2026 |
M(M-202) | May 15, 2020 |
New Product(NP) | May 10, 2016 |
New Chemical Entity Exclusivity(NCE) | May 10, 2018 |
New Indication(I-708) | Apr 30, 2018 |
NCE-1 date: 13 November, 2025
Market Authorisation Date: 12 May, 2023
Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, includin...
Dosage: POWDER;INHALATION